– SWITZERLAND, Eysins – Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, today announced the appointments of Dr. Isabelle Buckle and Dr. Catherine Larue to its Board of Directors effective later this year.
“We are delighted to welcome Dr Buckle and Dr Larue to our Board. They join Quotient at a particularly innovative and dynamic time, as we continue to expand our portfolios and drive our strategy forward building new relationships with stakeholders. They bring decades of experience in scientific commercial business development and biomedical research and development, respectively. We are very fortunate to have them by our side,” said Board Chairman, Heino von Prondzynski.
The company also announced that Sarah O’Connor and Thomas Bologna will be leaving the board effective September 1. They have advised the Company that they will not stand for re-election at the upcoming annual general meeting in October 2020. Ms. O’Connor and Mr. Bologna joined the board in 2014 and 2012, respectively.
Mr. von Prondzynski said, “Ms. O’Connor and Mr. Bologna have made enormous contributions to Quotient. It is to their credit that the Company stands in such a solid position today. On behalf of the entire board, we wish them all the best in their future endeavors.”
About Dr. Isabelle Buckle
Dr. Buckle currently serves as Executive Vice-President of Technology Transfer and Industrial Partnership at Institut Pasteur in Paris, France. Previously, Dr. Buckle served as Global Vice President, Clinical Mass Spectrometry at Bruker Daltonics. Prior to that, she was CEO and Chairman of InGEN Biosciences. Dr. Buckle has over 25 years of scientific, commercial and business experience in the biotechnology sector. Dr. Buckle holds a Ph.D. in Biochemistry from the University Paris VII, Institut Pasteur.
About Dr. Catherine Larue
Dr. Larue currently serves as the Director of External Affairs at the Integrated Biobank of Luxemburg and previously served as IBBL’s CEO. Prior to that, Dr. Larue led a business unit at Bio-Rad Laboratories, Inc. She sits on the boards of Fondation ARC, a public-interest organization focused on cancer research, GENFIT a biopharmaceutical company, and Information Technology for Translational Medicine, a clinical data processing company. Dr. Larue holds a Ph.D. in immunology from the University of Rouen and a master’s in business administration from St. John’s University and ISM Paris.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, and deliver significant workflow improvements and operational cost savings to laboratories around the world. Building on the experience from transfusion diagnostics, Quotient has now developed a serological test in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and available for distribution in Europe including Switzerland, and the UK. Quotient’s operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are trademarks or registered trademarks of Quotient Limited or its subsidiaries in various jurisdictions.
For more information : https://www.quotientbd.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
